Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market DemandPRNewsWire • 03/11/24
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTPRNewsWire • 02/26/24
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBPRNewsWire • 02/23/24
NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)Business Wire • 01/08/24
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid TumorsBusiness Wire • 01/03/24
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®PRNewsWire • 01/02/24
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 MutationPRNewsWire • 12/11/23
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid LeukemiaPRNewsWire • 12/11/23
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & ExpositionPRNewsWire • 12/08/23
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy CombinationsPRNewsWire • 11/06/23
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA TrialPRNewsWire • 11/02/23
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell TherapyPRNewsWire • 10/04/23
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual MeetingPRNewsWire • 09/27/23
Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?Seeking Alpha • 09/15/23
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHOPRNewsWire • 09/07/23
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual MeetingPRNewsWire • 08/31/23
NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire • 08/29/23
Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 CongressPRNewsWire • 08/21/23
Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals SummitPRNewsWire • 07/24/23
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire • 06/27/23